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Background: There is strong evidence on the efficacy of behavioral modification and treatment for reducing
diabetes incidence and diabetes-related morbidity and mortality in persons with pre-diabetes and diabetes. But the
extent to which the evidence has translated into gains in health in these population sub-groups in the US is
unclear. Monitoring national diabetes-related mortality levels over time is important for evaluating the effectiveness
of the US health system response to diabetes.
Methods: We identified individuals with pre-diabetes and diabetes using Hemoglobin A1c. Two consecutive
periods for investigating differences in mortality according to categories of glycemia were derived using nationally
representative survey data on US adults ages 35–74 from subsequent rounds of the National Health and Nutrition
Examination Survey (1988–1994 and 1999–2002). Age-standardized mortality rates were calculated for individuals
with pre-diabetes and diabetes and proportional hazards models were used to assess change in the relative risks of
dysglycemia (pre-diabetes and diabetes) adjusting for multiple confounding factors.
Results: Age-standardized mortality rates in individuals with pre-diabetes and diabetes showed no statistically
significant change between 1988–2001 and 1999–2006. In individuals with pre-diabetes, mortality rates were 11.19
and 14.02 deaths per 1,000 person-years in the early and later period, respectively. The corresponding values for
individuals with diabetes were 20.34 and 20.82 deaths per 1,000 person-years. In contrast, the absolute level of
mortality in the normo-glycemic population declined significantly between 1988–2001 and 1999–2006 (7.81 to 6.04;
p for difference < 0.05). Adjusting for social and demographic variables, smoking and body mass index in a
multivariate analysis, the hazard ratio of dysglycemia increased from 1.62 (95% CI: 1.36–1.93) in 1988–2001 to 2.36
(95% CI: 1.70–3.27) in 1999–2006 (p for difference < 0.05).
Conclusions: We find no evidence of declines in excess mortality in persons with dysglycemia between 1988–2001
and 1999–2006, a result that was robust to adjustment for social and demographic variables, smoking and body
mass index. In the context of long-term secular declines in mortality in the US population, our findings suggest that
individuals with pre-diabetes and diabetes should be an important focus of future interventions aimed at
improving population health in the US.
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Diabetes mellitus is a leading cause of death in the US
[1]. Clinical trial data have demonstrated the efficacy of
lifestyle and pharmacological interventions for reducing
the incidence and complications of diabetes [2-5]. Con-
current management of cardiovascular risk factors in
individuals with diabetes has shown to result in particu-
larly large improvements in health outcomes [6,7].
Despite the demonstrated efficacy of primary and
secondary diabetes prevention strategies, achieving
improved population health outcomes in practice
requires aggressive screening and overcoming the
complexities of managing diabetes and associated
conditions. Diabetes management requires long-term
medical care, input and coordination across health
providers, patient self-education and motivation and
addressing multiple behavioral, metabolic and cardiovas-
cular risk factors simultaneously [8]. Previous studies have
used diabetes as an indicator of health systems perfor-
mance in recognition that successful implementation of
these strategies relies centrally on high quality and
coordinated health care [9].
Evidence on the processes of care for individuals with
diagnosed diabetes for the 1990s and early 2000s
indicates that treatment rates have improved, but that
cardiovascular risk factor control remains sub-standard
[10-12]. With respect to glycemic control, little to no
change was observed over this period [11,12]. Informa-
tion on mortality trends in individuals with pre-diabetes
and diabetes is critical for a full assessment of progress
towards the more effective control of diabetes-related
outcomes in the US population. Trends have been
assessed in three previous nationally representative stud-
ies of the US population [13-15]. In all of the previous
studies, individuals with diabetes were identified using
self-reported data on having ever received a diagnosis of
diabetes by a health care provider. However, diagnostic
criteria [16] and levels of screening [17,18] have changed
over time, affecting selection into the population with
diagnosed diabetes and complicating interpretation of
trends. Also, because diabetes is undiagnosed in a third
to a fifth of US adults with the condition depending on
the criterion used [19], trends identified in prior studies
may not reflect trends occurring among the overall dia-
betic population. Information on trends in the overall
population with diabetes is important for a more
complete assessment of the health system response to
diabetes, the success of which depends both on diagnosis
and control of diabetes.
In this study, we investigate change over time in abso-
lute and excess mortality rates in individuals with pre-
diabetes and diabetes (collectively, ‘dysglycemia’) during
the period 1988–2006, which is the most recent period
for which nationally representative data are available.We extend the focus to individuals with pre-diabetes as
this group is at high risk for developing diabetes and its
complications and is considered a high-priority group
for intervention [8]. We use a clinical diagnostic meas-
ure, Hemoglobin A1c (HbA1c), to identify individuals
with dysglycemia and adjust for key confounding factors
in a multivariate analysis of mortality change.
Methods
We established two consecutive periods for investigating
mortality change according to diabetes status using data
from the National Health and Nutrition Examination
Survey (NHANES). NHANES is a series of nationally
representative surveys of the non-institutionalized U.S.
population conducted by the National Center for Health
Statistics (NCHS). The survey includes an examination
component in which extensive medical data are
collected by trained nurses in mobile clinics or in home-
visits and is linked to the National Death Index, a
computerized index of death record information
maintained by the NCHS [20]. The earlier period in our
analysis was constructed using data from 1988–1994
(NHANES III) and the later period using data from
1999–2002 (NHANES CTS). To reduce bias that may
result from differential follow-up across the two mortal-
ity periods, we restricted mortality follow-up in
NHANES III to 7.7 years, the maximum follow-up avail-
able in NHANES CTS. The resulting periods for our
analysis of mortality change were 1988–2001 for
NHANES III and 1999–2006 for NHANES CTS.
We restricted the sample to individuals ages 35–74
who underwent examination and had non-missing infor-
mation on diabetes and death (3.7% and 0.1% of persons
were missing information on each of these items). The
resulting sample included 9,210 observations on the
earlier cohort and 5,470 observations on the later co-
hort. We defined diabetes on the basis of the HbA1c
test, which is standardized to the methods of the Dia-
betes Control and Complications Trial in both periods
[21]. A distinct advantage of HbA1c is that it reflects
average glycaemia over a prolonged period of time and
exhibits greater pre-analytic stability and lower intra-
individual variation than other diagnostic markers, such
as fasting plasma glucose (FPG) [22]. We used the most
recent national American Diabetes Association (ADA)
guidelines [8] to classify individuals into categories of
non-diabetes (HbA1c less than 5.7%), pre-diabetes
(HbA1c between 5.7% and 6.5%) or diabetes (HbA1c
more than 6.5%). We further classified as diabetic per-
sons whose HbA1c values were below 6.5% but who
reported use of an oral hypoglycemic agent or insulin.
When referring collectively to individuals with pre-
diabetes and diabetes, we use the term ‘dysglycemia’. To
minimize bias, we did not consider information on
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changed over the period of analysis [23]. Approximately
1% of normo-glycemic individuals not currently taking
medications for diabetes reported a previous diagnosis
of the condition.
We calculated age-standardized mortality rates separ-
ately by diabetes status and period as the ratio of deaths
to person-years of follow-up, in each case using the year
2000 Census population as the standard. Within each
period, we calculated relative risks comparing pre-
diabetes and diabetes categories to no diabetes.
We also implemented Cox proportional hazards
models to estimate mortality risks associated with pre-
diabetes and diabetes adjusted for covariates and to test
for the significance of differences in these risks across
periods. Attained age was used as analysis time. We
imputed missing covariate values using multiple imput-
ation with Amelia II software [24,25]. The imputation
model included all model covariates, including
transformations. Overall, 1.1% of persons were missing
information on BMI, 0.5% on education and 0.1% on
smoking. Changes in the hazard ratios were estimated
by introducing an interaction into the model between
diabetes status and an indicator variable for period. We
initially assessed whether the proportionate change in
the hazard ratios differed across the two dysglycemic
groups. The two values were statistically indistinguish-
able from one another; therefore in subsequent analysis
we pooled individuals with pre-diabetes and diabetes
into a dysglycemic group. We additionally examined
sex-specific differences in the interaction, but found no
statistical differences by sex so we present results for the
sexes combined. In Model 1, we adjusted for social and
demographic covariates, including sex, race/ethnicity
(indicators for non-Hispanic black and Hispanic ethni-
city) and education (less than high-school education,
high-school education and more than high-school edu-
cation). In Model 2, we additionally adjusted for smok-
ing using categories of current, former and never
smoker. In Model 3, we extended Model 2 by including
linear and quadratic terms for body mass index (BMI)
[26]. We adjusted for smoking and BMI as they are
strong correlates of diabetes and previous research
suggests that smoking cessation may increase the risks
of developing diabetes [27,28].
We introduced interaction terms between each
covariate and analysis time into the model to check the
validity of the proportional hazards assumption. As the
assumption was not met for some covariates (black/non-
black and education), we re-estimated Models 1–3
retaining these particular interactions. We found that
results were not sensitive to their inclusion. All results
incorporated sampling weights which capture unequal
probabilities of selection and non-response adjustmentsand accounted for the complex survey design of
NHANES. Analyses were conducted using STATA 12
(StataCorp, Texas, USA).
Results
Table 1 shows descriptive characteristics of the US adult
population by diabetes status and period. In both
periods, individuals in the dysglycemic groups were gen-
erally older, less educated, and more likely to be His-
panic or non-Hispanic black compared to those without
diabetes. Changes over time in the distribution of smok-
ing status and body mass index (BMI) differed across
the three groups. The proportion of current smokers
declined significantly over time for the pre-diabetic
group (37.63% to 22.13%; p < 0.05), but not for the non-
diabetic (25.43% to 23.91%) and diabetic groups (22.01%
to 19.13%). Larger increases in the percentage of never
smokers were observed in persons with dysglycemia
compared to those without. The proportion with severe
obesity (BMI ≥ 35 kg/m2) increased in all groups, but
somewhat larger absolute increases were observed in
individuals with dysglycemia (differential increase of 5%
[95% CI 1-10%; p < 0.05]). The proportion with severe
obesity was three times higher among individuals with
diabetes than among those without diabetes in the more
recent period. Table 1 also shows mean HbA1c levels,
which remained essentially unchanged between periods
for individuals with pre-diabetes and diabetes.
Table 2 shows age-standardized mortality rates and
relative risks by diabetes status and period. Whereas the
age-standardized mortality rate in the normo-glycemic
population declined significantly between 1988–2001
and 1999–2006 (7.81 to 6.04; p for difference < 0.05), ab-
solute levels of mortality among individuals with pre-
diabetes and diabetes showed no statistically significant
change. The mortality rate increased from 11.19 to 14.02
deaths per 1,000 person-years in individuals with pre-
diabetes and from 20.34 to 20.82 deaths per 1,000
person-years in individuals with diabetes. Relative risks
of mortality grew across periods for both individuals
with pre-diabetes (1.43 to 2.32) and those with diabetes
(2.60 to 3.45). These changes were equivalent to
increases of 62% and 32% in the relative risks and were
not statistically significant.
The differences in mortality across the two periods in
Table 2 may partially reflect changes in background factors
related to both diabetes and mortality, such as race/ethni-
city, education, smoking and BMI. Table 3 shows results
from multivariate proportional hazards models adjusting
for these covariates. In these models, the hazard ratio of
the ‘dysglycemia x period’ term expresses the proportion-
ate change in the hazard ratio associated with dysglycemia
from the earlier to the later mortality period (1988–2001
to 1999–2006). In Model 1, adjusting for social and
Table 1 Descriptive statistics of the U.S. adult population ages 35-74 by diabetes status and period
No Diabetes Pre-Diabetes Diabetes
NHANES III NHANES CTS NHANES III NHANES CTS NHANES III NHANES CTS
Sample size 6,277 4,014 1,679 660 1,254 796
Mean age, y 49.45 49.47 56.19 55.52 57.11 56.99
Hispanic,% 7.62 10.84 10.26 15.65 11.25 16.91
Non-Hispanic Black,% 7.32 8.71 20.07 16.67 17.69 17.79
Education,%
Less than High School 20.99 17.66 † 35.63 29.06 44.35 37.61
High School 33.21 24.45 † 35.56 28.52 † 33.15 24.84 †
More than High School 45.80 57.89 † 28.82 42.42 † 22.51 37.55 †
Smoking Status,%
Current 25.43 23.91 37.63 22.13 † 22.01 19.13
Former 31.51 28.51 † 30.04 33.85 40.98 34.56
Never 43.06 47.58 † 32.33 44.02 † 37.02 46.31 †
Mean BMIa (kg/m2) 26.69 27.73 † 28.85 31.74 † 31.41 32.86 †
BMIa category (kg/m2),%
30 to 35 15.09 17.41 † 20.34 31.98 † 28.25 25.68
More than 35 6.88 10.48 † 15.33 24.27 † 26.20 33.15 †
Mean HbA1c 5.16 5.24 † 5.99 5.97 8.11 8.00
BMI: body mass index; HbA1c: Hemoglobin A1c; a. BMI derived from measure data on height and weight; No Diabetes is defined as HbA1c less than 5.7%;
Pre-Diabetes is defined as HbA1c between 5.7 and 6.5%; Diabetes is defined as HbA1c above 6.5% or on treatment for diabetes. Sources: National Health and
Nutrition Examination Survey (NHANES) III (1988–1994) and continuos (CTS) (1999–2002).
† Significantly different (p < 0.05) compared with NHANES III.
Table 2 All-cause mortality rates (per 1,000 person-years)
and relative risks for the US adult population by
diabetes status and period
NHANES III NHANES CTS
(1988-2001) (1999-2006)
No Diabetes
Mortality Rate 7.81 (6.70-8.93) 6.04 (4.77-7.32) †
Relative Risk 1.00 1.00
Pre-Diabetes
Mortality Rate 11.19 (8.38-14.00) 14.02 (8.47-19.58)
Relative Risk 1.43 (1.12-1.74) 2.32 (1.24-3.40)
Diabetes
Mortality Rate 20.34 (16.00-24.67) 20.82 (13.10-28.54)
Relative Risk 2.60 (1.91-3.29) 3.45 (2.02-4.87)
Deaths 960 341
Person-years 67,526 30,989
HbA1c: Hemoglobin A1c; No Diabetes is defined as HbA1c less than 5.7%; Pre-
Diabetes is defined as HbA1c between 5.7 and 6.5%; Diabetes is defined as
HbA1c above 6.5% or on treatment for diabetes. Sample includes persons ages
35-74 at baseline. Entry years are 1988-1994 with follow-up through 2001 for the
earlier period and 1999-2002 with follow-up through 2006 for the later period.
Mortality rates are age-standardized to the year 2000 Census population using
age groups 35-54, 55-69 and 70-84. Relative risks are based on age-standardized
mortality rates and are otherwise unadjusted. All estimates are weighted and
account for complex survey design. Sources: National Health and Nutrition
Examination Survey (NHANES) III and continuous (CTS).
†Significantly different (p < 0.05) compared with NHANES III.
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1.63 (95% CI: 1.38-1.92) in 1988–2001. The hazard ratio
of the two-way interaction indicated that the relative risks
increased by 34% across the two periods; however the dif-
ference was not significant. Multiplying these two terms
yields a hazard ratio for dysglycemia of 2.18 (95% CI: 1.57-
3.04) in the later period (1999–2006).
When smoking was included in the model, we
observed a statistically significant increase in the hazard
ratio for dysglycemia across the two periods (HR = 1.45
for the interaction term; 95% CI: 1.02-2.07). In Model 2,
the hazard ratio of dysglycemia was 1.55 (95% CI: 1.31-
1.83) in 1988–2001 and 2.26 (95% CI: 1.64-3.11) in
1999–2006. The increase in the magnitude of the inter-
action term between Model 1 and Model 2 was due to
both a slight decline in the hazard ratio in the early
period (from 1.63 to 1.55) and a slight increase in the
hazard ratio applicable to the later period (2.18 to 2.26).
These changes are likely attributable to the changing as-
sociation between smoking and diabetes status across
time as shown in Table 1. Additional adjustment for
BMI and BMI-squared had little effect on the magnitude
of the estimated change (Model 3).
Discussion
In this paper, we investigated mortality of individuals
with dysglycemia relative to individuals with normo-
Table 3 Hazard ratios predicting mortality from all causes
Model 1 Model 2 Model 3
Hazard Ratio 95% CI Hazard Ratio 95% CI Hazard Ratio 95% CI
Sex
Women 1.00 1.00 1.00
Men 1.54 *** (1.34-1.76) 1.30 *** (1.13-1.50) 1.33 *** (1.16-1.53)
Race/ethnicity
Other 1.00 1.00 1.00
Hispanic 0.76 (0.57-1.02) 0.83 (0.62-1.12) 0.84 (0.63-1.13)
Non-Hispanic Black 1.48 *** (1.21-1.82) 1.51 *** (1.23-1.84) 1.49 *** (1.22-1.81)
Education Level
Less than High School 1.00 1.00 1.00
High School 0.78 ** (0.65-0.93) 0.79 ** (0.66-0.94) 0.79 ** (0.67-0.94)
More than High School 0.61 *** (0.50-0.74) 0.68 *** (0.56-0.83) 0.67 *** (0.55-0.82)
Smoking
Never Smoker 1.00 1.00
Former Smoker 1.83 *** (1.46-2.29) 1.83 *** (1.46-2.39)
Current Smoker 2.90 *** (2.24-3.75) 2.73 *** (2.11-3.52)
BMI 0.87 *** (0.82-0.93)
BMI Squared 1.00 *** (1.00-1.00)
Perioda 0.86 (0.65-1.13) 0.86 (0.66-1.13) 0.88 (0.67-1.15)
Dysglycemiab 1.63 *** (1.38-1.92) 1.55 *** (1.31-1.83) 1.62 *** (1.36-1.93)
Dysglycemia X Period 1.34 (0.94-1.92) 1.45* (1.02-2.07) 1.46 * (1.03-2.08)
a. Period is an indicator variable which takes a value of 1 in the later of the two periods in the analysis. Entry years are 1988-1994 with follow-up through 2001 for
the earlier period and 1999-2002 with follow-up through 2006 for the later period; b. Dysglycemia sample includes persons with HbA1c ≥ 5.7% or on treatment for
diabetes. References categories for categorical variables indicated by HR = 1.00; Sample includes persons ages 35-74 at baseline. All estimates are weighted and
account for complex survey design.
Sources: National Health and Nutrition Examination Survey III and continuous.
***p < 0.001; ** < 0.01; *p < 0.05
Stokes and Mehta Population Health Metrics 2013, 11:3 Page 5 of 7
http://www.pophealthmetrics.com/content/11/1/3glycemia and the extent to which the level of excess
mortality associated with dysglycemia, adjusting for
confounding factors, has changed over the period 1988–
2006. Whereas the age-standardized mortality rate
declined significantly between periods in the normo-
glycemic population, mortality rates in individuals with
pre-diabetes and diabetes showed no clear evidence of
change. In our multivariate analysis, dysglycemia was
associated with a non-significant increase in mortality
over time in a model that adjusted for socio-demographic
characteristics. However, a more pronounced and
statistically significant increase in excess risk was observed
upon further adjustment for smoking, suggesting that
secular trends in smoking and its distribution by diabetes
status may partially obscure change in the mortality risks
of dysglycemia. Our multivariate results, based on
adjustment for social and demographic variables,
smoking and body mass index, indicated a 46% increase
in the relative risk of dysglycemia for the US adult
dysglycemic population.
Our findings follow on two previous nationally repre-
sentative studies that have documented increasing gapsin mortality between individuals with and without dia-
betes. Excess mortality risks for those who reported a
diabetes diagnosis were found to have increased over the
1970s and 1980s [13]. In a subsequent study that
included more recent cohort experience from years
1988–1994 and mortality follow-up through 2001 excess
mortality appeared to increase among women but not in
men with diabetes relative to 1976–1980 [14].
Diabetes-related mortality trends have also been
investigated using data from the Framingham Heart
Study [29]. This study used clinically measured glucose
levels and found that excess mortality declined between
1950–1979 and 1976–2005. However, in a sensitivity
analysis in which the authors investigated trends in a
more recent and narrow time interval (1971 to 2000), no
statistically significant declines in absolute or excess all-
cause mortality were identified.
Our findings contrast with those of a recent study that
investigated three-year US mortality rates across four
cohorts (1997–1998, 1999–2000, 2001–2002 and 2003–
2004) using data from the National Health Interview
Survey [15]. This study found declines in excess
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betes between 1997–1998 and 2003–2004. However, as
one-third to one-fifth of the diabetic population is un-
diagnosed [19], trends identified in the prior study may
not be reflective of those for the entire adult population
with diabetes. Criteria for diagnosis and screening of dia-
betes changed over the period of the analysis, further
complicating interpretation of trends based on self-
reported data for defining diabetes. With respect to diag-
nostic criteria, in 1997 the ADA established new
guidelines for the diagnosis of diabetes, based on FPG,
which lowered the threshold of diagnosis from 140 mg/dL
to 126 mg/dL [23]. Any changes in the severity distribu-
tion of diabetes induced by the change in guidelines,
which are likely to have been implemented gradually over
time, would have likely biased trends estimates using self-
reported data. Secular increases in screening may have
also affected the composition of the population with
diabetes over the two periods, by increasing the proportion
of diabetes cases detected early. However, in a sensitivity
analysis, the findings of the prior study were found to be
robust to the exclusion of individuals with recent onset
diabetes (2 years or less) [15].
Our consideration of individuals with pre-diabetes as
well as those with diabetes may have also contributed to
the differences in findings between the two studies.
Given the absence of population-based screening in the
US, individuals with non-diabetic dysglycemia may have
benefited less from health services than individuals with
diabetes, leading to lower likelihoods of mortality
improvements over time in that sub-population. Finally,
differences between studies could relate to the fact that
HbA1c may identify a somewhat different subset of
individuals with diabetes than FPG and other diagnostic
measures in common use [19].
Our results also differ with evidence from the UK,
where inequalities in mortality between individuals with
and without diabetes are reported to have declined in
the interval 1996–2006 [30]. Health systems factors may
partially account for these differences [31]. One study
points to improved management of diabetes in the UK
compared to the US [32].
A key strength of our analysis is our use of HbA1c cri-
teria rather than self-report to identify individuals with
dysglycemia. To our knowledge, this is the first study to
use an objective blood marker in the examination of na-
tional diabetes-related mortality change in the US. An
additional strength of our study is that we included
adjustments for key confounding variables, such as obes-
ity and smoking, in our multivariate analysis. Our ana-
lysis was limited by small sample sizes, which prevented
an investigation of the role of specific causes of death or
a more detailed exploration of the mechanisms under-
lying increased relative mortality risks between the twoperiods. For example, one factor that may have
contributed is an increase in the incidence of diabetes
among individuals with dysglycemia across the two time
periods. Although we detected no significant differences
in the extent of mortality change between persons with
pre-diabetes vs. diabetes or in men vs. women, there
may be sub-group heterogeneity that we could not dis-
cern given limited statistical power. Future research
should explore mortality trends in specific population
sub-groups defined by diabetes and sex, investigate
trends across cohorts more narrowly defined in calendar
years and explore the sensitivity of trends to the use of
alternate diagnostic measures of diabetes, such as FPG.
We cannot rule out the possibility that our findings are
affected by residual confounding. For example, adjust-
ment for BMI at baseline may not have fully captured
patterns of change in the duration of obesity [33], cen-
tral adiposity and other features of the metabolic
syndrome.
In conclusion, we find no evidence that excess mortal-
ity in US adults with dysglycemia decreased over the
interval 1988–2006. These findings were not explained
by age, race or ethnicity, education, smoking or rising
BMI levels in persons with dysglycemia. When
contrasted with the long-term secular declines in all-
cause and cardiovascular mortality in the US population
[34], the lack of improvement in mortality in the
dysglycemic population is concerning and suggests that
individuals with pre-diabetes and diabetes should be an
important focus of future interventions aimed at im-
proving population health in the US.
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